News

Catch up on this week's highlights in retina.

Jeremiah Tao, MD, FACS, used his Egyptian Ophthalmological Society keynote to explore complex and costly challenges in oculofacial surgery

Recapping the Heidelberg Engineering International SPECTRALIS Symposium—and Beyond.

Researchers used adaptive optics scanning light ophthalmoscopy (AOSLO) to study retinas in mice with photoreceptor damage, specifically photoreceptor laser injury.

Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings

Advancements in retinal therapies and technologies are scheduled to be showcased at EURETINA 2025 from Clearside, ZEISS, and Ashvattha Therapeutics.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration.

As myopia becomes a worldwide epidemic, the upcoming Paris workshop on September 8, 2025, will convene global leaders to discuss strategies, research priorities, and new treatment pathways.

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration

Ahead of the September 8 meeting in Paris, the program co-chair of the event and current president of the American Academy of Ophthalmology discusses how the workshop aims to shape consensus on guidelines, research priorities, and emerging therapies in myopia control.

A novel use of minor salivary glands offers lasting relief and visual improvement.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Where to find members of our editorial board at this year's European Society of Retina Specialists Congress

At the 2025 EURETINA Congress, keep an eye out for 11 editorial advisory board members from Modern Retina, Ophthalmology Times and Ophthalmology Times Europe.

Long-term cannabis use may reduce the risk of proliferative vitreoretinopathy after retinal detachment surgery, suggesting potential therapeutic benefits.

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

Innovation, adaptability, and clear communication are key to managing outcomes.

Revisiting a classic tool that still gets you out of a jam works best when you understand its powers and limitations.

Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France

Retina specialists will celebrate the major anniversary this September in Paris, France.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.